Fluvastatin inhibits hepatitis C replication in humans (Q34769764)

4 August 2017

Fluvastatin inhibits hepatitis C replication in humans (English)

1 reference

4 August 2017

1 reference

Ted Bader

1

1 reference

4 August 2017

Javid Fazili

2

1 reference

4 August 2017

Mohammed Madhoun

3

1 reference

4 August 2017

Christopher Aston

4

1 reference

4 August 2017

Diane Hughes

5

1 reference

4 August 2017

Syed Rizvi

6

1 reference

4 August 2017

Ken Seres

7

1 reference

4 August 2017

Muhammad Hasan

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

14 April 2008

1 reference

The American Journal of Gastroenterology

4 August 2017

1 reference

4 August 2017

103

1 reference

4 August 2017

1383-1389

1 reference

4 August 2017

6

1 reference

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

4 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Hepatitis C virus particles and lipoprotein metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Mechanisms and significance of liver steatosis in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Antiviral action of ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Hepatitis C Lipo-Viro-Particle from Chronically Infected Patients Interferes with TLR4 Signaling in Dendritic Cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Incidence of statin hepatotoxicity in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2008.01876.X

10.1111/J.1572-0241.2008.01876.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference